Partnerships, Licensing, Investments and M&A Deals and Trends for March 2016 in Pharmaceuticals

Home/Partnerships, Licensing, Investments and M&A Deals and Trends for March 2016 in Pharmaceuticals

Partnerships, Licensing, Investments and M&A Deals and Trends for March 2016 in Pharmaceuticals

Regulation & Policy (Pharma & Healthcare), Finance & Investment (Pharma & Healthcare), Deals & Alliances (Pharma & Healthcare), Pharma & Healthcare

Publication ID:

GDA0516012

Publication Date:

May 01, 2016

Pages:

Publisher:

GlobalData

Region:

Global

$1,000.00

Need Custom Market Research Solution?

Want to commission a custom market research to suit your needs? We are here to help. Let us know.

Printer version

Send by email

PDF version

Tabs

Description

Partnerships, Licensing, Investments and M&A Deals and Trends for March 2016 in Pharmaceuticals

Summary

GlobalData's “Partnerships, Licensing, Investments and M&A Deals and Trends for March 2016 in Pharmaceuticals” report is an essential source of data and trend analysis on partnerships, licensing, mergers and acquisitions (M&As) and financings in the pharmaceuticals industry. The report provides detailed information on partnership and licensing transactions, M&As, equity/debt offerings, private equity, and venture financing registered in the pharmaceuticals industry in March 2016. The report portrays detailed comparative data on the number of deals and their value in the last six months, subdivided by deal types, various therapy areas, and geographies. Additionally, the report provides information on the top financial advisory firms in the pharmaceuticals industry.

Data presented in this report is derived from GlobalData’s proprietary in-house Pharmaceuticals eTrack deals database and primary and secondary research.

Scope

- Analysis of the market trends for the pharmaceutical industry in the global arena.
- Review of deal trends in the cardiovascular, central nervous system, dermatology, ear nose throat disorders, gastrointestinal, genito urinary system and sex hormones, hematological disorders, hormonal disorders, immunology, infectious disease, male health, metabolic disorders, mouth and dental disorders, musculoskeletal, oncology, ophthalmology, respiratory, toxicology, and women's health segments.
- Analysis of partnerships, licensing, M&As, equity/debt offerings, private equity, and venture financing deals in the pharmaceutical industry.
- Analysis of therapy areas which are very active in terms of venture capital financing, partnerships, licensing agreements, equity/debt offerings, and M&As.
- Analysis of deals based on different payment modes, including upfront and milestone payments, primarily in partnerships and licensing agreements in the pharmaceutical industry.
- Analysis of partnership and licensing deals based on clinical stage of development of products.
- Summary of the pharmaceutical deals globally in the six months.
- Information on the top deals happened in the pharmaceutical industry.
- Geographies covered include - North America, Europe, Asia Pacific, South & Central America, and the Middle East & Africa.
- League tables of financial advisors in M&As and equity/debt offerings. This includes key advisors such as Morgan Stanley, Credit Suisse, and Goldman Sachs.

Reasons to buy

- Enhance your decision making capability in a more rapid and time sensitive manner.
- Find out the major deal performing segments for investments in your industry.
- Evaluate the types of companies which are entering into partnership or licensing agreements; divesting and acquiring assets.
- Identify companies that are aggressively looking to raise capital in the market
- Evaluate niche therapy areas that are receiving majority of the upfront and milestone payments in the pharmaceutical industry.
- Identify the key venture capitalists, who are financing the pharmaceutical and biotech companies.
- Evaluate the clinical development stages where majority of the partnerships and licensing agreements are happening.
- Do deals with an understanding of how competitors are financed, and the mergers and partnerships that have shaped the pharmaceutical industry.
- Identify growth segments and opportunities in each region within the industry.
- Look for key financial advisors where you are planning to raise capital from the market or for acquisitions within the industry.

Table of Contents

1 Table of Contents
1 Table of Contents 2
1.1 List of Tables 6
1.2 List of Figures 9
2 Pharmaceuticals & Healthcare, Global, Deal Summary 12
2.1 Pharmaceuticals & Healthcare, Global, Deal Analysis, March 2016 12
2.2 Pharmaceuticals & Healthcare, Global, Major Deals, March 2016 14
2.2.1 Sanofi Prices Public Offering of Notes For USD2 Billion 14
2.2.2 Perrigo Raises USD1.2 Billion in Public Offering of Notes 14
2.2.3 Shanghai Shyndec Pharma to Acquire Stakes in 12 Pharma Companies for USD1.2 Billion 15
2.2.4 AmerisourceBergen Raises USD1.17 Billion in Private Placement of Shares up on Exercise of Warrants 15
2.2.5 Royalty Pharma Acquires Royalty Rights of Xtandi from University of California, Los Angeles for USD1.14 Billion 15
2.3 Pharmaceuticals & Healthcare, Global, by Type, Number of Deals, March 2016 17
2.4 Pharmaceuticals & Healthcare, Global, by Type, Deal Values, March 2016 18
3 Pharmaceuticals and Healthcare, Global, Deals, Summary, by Type 19
3.1 Pharmaceuticals & Healthcare, Global, M&A, March 2016 19
3.1.1 Top M&A Deals in March 2016 20
3.1.2 Pharmaceuticals & Healthcare, Global, M&A Deals by Therapy Area, October 2015 - March 2016 21
3.2 Pharmaceuticals & Healthcare, Global, Equity Offering Deals, March 2016 22
3.2.1 Top Equity Offering Deals in March 2016 23
3.2.2 Pharmaceuticals & Healthcare, Global, Equity Offering Deals by Therapy Area, October 2015 - March 2016 24
3.3 Pharmaceuticals & Healthcare, Global, Private Equity and Venture Capital Deals, March 2016 25
3.3.1 Top PE/VC Deals in March 2016 26
3.3.2 Pharmaceuticals & Healthcare, Global, PE/VC by Therapy Area, March 2016 27
3.3.3 Pharmaceuticals & Healthcare, Global, Venture Capital Deals by Stage of Financing, March 2016 28
3.3.4 Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, October 2015-March 2016 30
3.3.5 Pharmaceuticals & Healthcare, Global, Top VC Backed Companies, October 2015-March 2016 31
4 Pharmaceuticals & Healthcare, Global, Partnership Deals, March 2016 32
4.1 Pharmaceuticals & Healthcare, Global, Partnership Deals, March 2016 32
4.2 Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, October 2015 - March 2016 34
4.3 Pharmaceuticals & Healthcare, Global, Partnership Deals by Upfront and Milestone Payments and Deal Values (US$ m), March 2016 35
4.3.1 Pharmaceuticals & Healthcare, Global, Top Partnership Deals by Payment Mode, March 2016 36
4.4 Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, by Upfront and Milestone Payments and Deal Values (US$ m), October 2015 - March 2016 37
4.5 Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, Number Of Deals, October 2015 - March 2016 39
4.6 Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, Deal Values (US$ m), October 2015 - March 2016 40
4.7 Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, by Upfront & Milestone Payments and Deal Values (US$ m), October 2015 - March 2016 42
5 Pharmaceuticals & Healthcare, Global, Licensing Agreements, March 2016 44
5.1 Pharmaceuticals & Healthcare, Global, Licensing Agreements, March 2016 44
5.2 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, Upfront and Milestone Payments and Deal Values (US$ m), March 2016 46
5.3 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Total Deal Values (US$ m), October 2015 - March 2016 48
5.4 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Upfront Payments and Milestone Payments (US$ m), October 2015 - March 2016 49
5.5 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, Total Deal Values (US$ m), October 2015 - March 2016 51
5.6 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, Upfront Payments and Milestone Payments (US$ m), October 2015 - March 2016 53
5.6.1 Pharmaceuticals & Healthcare, Global, Top Licensing Agreements by Deal Value, March 2016 54
5.6.2 Pharmaceuticals & Healthcare, Global, Top Licensing Agreements, by Total Upfront Payments, March 2016 55
5.6.3 Pharmaceuticals & Healthcare, Global, Top Licensing Agreements by Total Milestone Payment, March 2016 55
6 Pharmaceuticals & Healthcare, Global, Deal Summary by Therapy Area 56
6.1 Pharmaceuticals & Healthcare, Global, Oncology Deals, March 2016 56
6.1.1 Oncology - Deals of the Month 57
6.2 Pharmaceuticals & Healthcare, Global, Central Nervous System Deals, March 2016 60
6.2.1 Central Nervous System - Deals of the Month 61
6.3 Pharmaceuticals & Healthcare, Global, Infectious Disease Deals, March 2016 63
6.3.1 Infectious Diseases - Deals of the Month 64
6.4 Pharmaceuticals & Healthcare, Global, Cardiovascular Deals, March 2016 66
6.4.1 Cardiovascular - Deals of the Month 67
6.5 Pharmaceuticals & Healthcare, Global, Immunology Deals, March 2016 69
6.5.1 Immunology - Deals of the Month 70
6.6 Pharmaceuticals & Healthcare, Global, Gastrointestinal Deals, March 2016 72
6.6.1 Gastrointestinal - Deal of the Month 73
6.7 Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Deals, March 2016 75
6.7.1 Metabolic Disorders - Deal of the Month 76
7 Deal Summary by Geography 78
7.1 Pharmaceuticals & Healthcare, North America Deals, March 2016 78
7.1.1 North America - Deals of the Month 79
7.2 Pharmaceuticals & Healthcare, Europe, Deals, March 2016 82
7.2.1 Europe - Deals of the Month 83
7.3 Pharmaceuticals & Healthcare, Asia-Pacific, Regional Deals, March 2016 85
7.3.1 Asia-Pacific - Deals of the Month 86
7.4 Pharmaceuticals & Healthcare, Rest of the World, Deals, March 2016 88
7.4.1 Rest of the World - Deals of the Month 89
8 Pharmaceuticals & Healthcare, Global, Top Financial Advisors 90
8.1 Pharmaceuticals & Healthcare, Global, Top Financial Advisors, M&A, October 2015 - March 2016 90
8.2 Pharmaceuticals & Healthcare, Global, Top Financial Advisors, Equity Offerings, October 2015 - March 2016 92
9 Further Information 94
9.1 Methodology 94
9.2 About GlobalData 95
9.3 Disclosure information 95
9.4 Disclaimer 96

1.1 List of Tables
Table 1: Pharmaceuticals & Healthcare, Global, Deals Summary, Number of Deals and Deal Values (US$ m), October 2015 - March 2016 13
Table 2: Pharmaceuticals & Healthcare, Global, Major Deals, March 2016 14
Table 3: Pharmaceuticals & Healthcare, Global, Number Of Deals and Deal Values (%), March 2016 18
Table 4: Pharmaceuticals & Healthcare, Global, M&A, Deals Summary, Number of Deals and Deal Values (US$ m), October 2015 - March 2016 20
Table 5: Pharmaceuticals & Healthcare, Global, Top M&A Deals, March 2016 20
Table 6: Pharmaceuticals & Healthcare, Global, M&A, Deals Summary, Number of Deals and Deal Values (US$ m), by Therapy Area, October 2015 - March 2016 21
Table 7: Pharmaceuticals & Healthcare, Global, Equity Offerings, Deals Summary, Number of Deals and Deal Values (US$ m), October 2015 - March 2016 23
Table 8: Pharmaceuticals & Healthcare, Global, Top Equity Offering Deals, March 2016 23
Table 9: Pharmaceuticals & Healthcare, Global, Equity Offering Deals, Deals Summary, Number of Deals and Deal Values (US$ m), October 2015 - March 2016 24
Table 10: Pharmaceuticals & Healthcare, Global, PE/VC, Deals Summary, Number of Deals and Deal Values (US$ m), October 2015 - March 2016 26
Table 11: Pharmaceuticals & Healthcare, Global, Top PE/VC Deals, March 2016 26
Table 12: Pharmaceuticals & Healthcare, Global, PE/VC Deals by Therapy Area, Deals Summary, October 2015 - March 2016 27
Table 13: Pharmaceuticals & Healthcare, Global, Venture Capital Deals by Stage of Financing, Number Of Deals and Deal Values (%), March 2016 29
Table 14: Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, Number of Deals and Deal Values (US$ m), October 2015 - March 2016 30
Table 15: Pharmaceuticals & Healthcare, Global, Top VC Backed Companies, October 2015 - March 2016 31
Table 16: Pharmaceuticals & Healthcare, Global, Partnerships, Number of Deals and Deal Values (US$ m), October 2015 - March 2016 33
Table 17: Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, Number of Deals and Deal Values (US$ m), October 2015 - March 2016 34
Table 18: Pharmaceuticals & Healthcare, Partnership Deals, Upfront and Milestone Payments and Deal Values (US$ m), October 2015 - March 2016 35
Table 19: Pharmaceuticals & Healthcare, Global, Partnerships, Upfront and Milestone Payments and Deal Values (US$ m), March 2016 36
Table 20: Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, Upfront and Milestone Payments and Deal Values (US$ m), October 2015 - March 2016 38
Table 21: Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, October 2015 - March 2016 41
Table 22: Pharmaceuticals & Healthcare, Global, Partnership Deals by Upfront and Milestone Payment and Deal values (US$ m), October 2015 - March 2016 43
Table 23: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, Deals Summary, Number of Deals and Deal Values (US$ m), October 2015 - March 2016 45
Table 24: Pharmaceuticals & Healthcare, Global, Licensing Agreements, Deals Summary, Upfront and Milestone Payments and Deal Values (US$ m), October 2015 - March 2016 47
Table 25: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Number of Deals and Deal Values (US$ m), October 2015 - March 2016 48
Table 26: Pharmaceuticals & Healthcare, Global, Licensing Agreements by Therapy Area, by Upfront and Milestone Payments (US$ m), March 2016 50
Table 27: Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, October 2015 - March 2016 52
Table 28: Pharmaceuticals & Healthcare, Global, Licensing Agreements by Therapy Area, by Upfront and Milestone Payments and Deal Values (US$ m), March 2016 54
Table 29: Pharmaceuticals & Healthcare, Global, Top Licensing Agreement Deals by Value, March 2016 54
Table 30: Pharmaceuticals & Healthcare, Global, Top Licensing Agreement Deals by Total Upfront Payments, March 2016 55
Table 31: Pharmaceuticals & Healthcare, Global, Top Licensing Agreement Deals by Total Milestone Payment, March 2016 55
Table 32: Pharmaceuticals & Healthcare, Global, Oncology, Deals Summary, Number of Deals and Deal Values (US$ m), October 2015 - March 2016 57
Table 33: Pharmaceuticals & Healthcare, Global, Central Nervous System, Deals Summary, Number of Deals and Deal Values (US$ m), October 2015 - March 2016 61
Table 34: Pharmaceuticals & Healthcare, Global, Infectious Diseases, Deals Summary, Number of Deals and Deal Values (US$ m), October 2015 - March 2016 64
Table 35: Pharmaceuticals & Healthcare, Global, Cardiovascular, Deals Summary, Number of Deals and Deal Values (US$ m), October 2015 - March 2016 67
Table 36: Pharmaceuticals & Healthcare, Global, Immunology, Deals Summary, Number of Deals and Deal Values (US$ m), October 2015 - March 2016 70
Table 37: Pharmaceuticals & Healthcare, Global, Gastrointestinal, Deals Summary, Number of Deals and Deal Values (US$ m), October 2015 - March 2016 73
Table 38: Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Deals Summary, Number of Deals and Deal Values (US$ m), October 2015 - March 2016 76
Table 39: Pharmaceuticals & Healthcare, North America, Deals Summary, Number of Deals and Deal Values (US$ m), October 2015 - March 2016 79
Table 40: Pharmaceuticals & Healthcare, Europe, Deals Summary, Number of Deals and Deal Values (US$ m), October 2015 - March 2016 83
Table 41: Pharmaceuticals & Healthcare, Asia-Pacific, Deals Summary, Number of Deals and Deal Values (US$ m), October 2015 - March 2016 86
Table 42: Pharmaceuticals & Healthcare, Rest of the World, Deals Summary, Number of Deals and Deal Values (US$ m), October 2015 - March 2016 89
Table 43: Pharmaceuticals & Healthcare, Top Financial Advisors, M&A, Number of Deals and Deal Values (US$ m), October 2015 - March 2016 91
Table 44: Pharmaceuticals & Healthcare, Global Top Financial Advisors, Equity Offerings, Number of Deals and Deal Values (US$ m), October 2015 - March 2016 93

1.2 List of Figures
Figure 1: Pharmaceuticals & Healthcare, Global, Number of Deals and Deal Values (US$ m), October 2015 - March 2016 12
Figure 2: Pharmaceuticals & Healthcare, Global, Number Of Deals (%), March 2016 17
Figure 3: Pharmaceuticals & Healthcare, Global, Deal Values (%), March 2016 18
Figure 4: Pharmaceuticals & Healthcare, Global, M&As, Number of Deals and Deal Values (US$ m), October 2015 - March 2016 19
Figure 5: Pharmaceuticals & Healthcare, Global, M&As by Therapy Area, Number of Deals and Deal Values (US$ m), by Therapy Area, October 2015 - March 2016 21
Figure 6: Pharmaceuticals & Healthcare, Global, Equity Offering Deals, Number of Deals and Deal Values (US$ m), October 2015 - March 2016 22
Figure 7: Pharmaceuticals & Healthcare, Global, Equity Offering Deals by Therapy Area, Number of Deals and Deal Values (US$ m), October 2015 - March 2016 24
Figure 8: Pharmaceuticals & Healthcare, Global, Private Equity and Venture Capital, Number of Deals and Deal Values (US$ m), October 2015 - March 2016 25
Figure 9: Pharmaceuticals & Healthcare, Global, PE/VC Deals by Therapy Area, Number of Deals and Deal Values (US$ m), by Therapy Area, October 2015 - March 2016 27
Figure 10: Pharmaceuticals & Healthcare, Global, Venture Capital Deals by Stage of Financing, Number Of Deals (%), March 2016 28
Figure 11: Pharmaceuticals & Healthcare, Global, Venture Capital Deals by Stage of Financing, Deal Values (%), March 2016 29
Figure 12: Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, Number of Deals and Deal Values (US$ m), October 2015 - March 2016 30
Figure 13: Pharmaceuticals & Healthcare, Global, Partnerships, Number of Deals and Deal Values (US$ m), October 2015 - March 2016 32
Figure 14: Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, Number of Deals and Deal Values (US$ m), October 2015 - March 2016 34
Figure 15: Pharmaceuticals & Healthcare, Global, Partnership Deals, Upfront and Milestone Payments and Deal Values (US$ m), October 2015 - March 2016 35
Figure 16:Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, Upfront and Milestone Payments and Deal Values (US$ m), October 2015 - March 2016 37
Figure 17: Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, October 2015 - March 2016 39
Figure 18: Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, October 2015 - March 2016 40
Figure 19: Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, by Upfront & Milestone Payments and Deal Values (US$ m), October 2015 - March 2016 42
Figure 20:Pharmaceuticals & Healthcare, Global, Licensing Agreements, Number of Deals and Deal Values (US$ m), October 2015 - March 2016 44
Figure 21:Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, Upfront and Milestone Payments and Deal Values (US$ m), October 2015 - March 2016 46
Figure 22:Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Number of Deals and Deal Values (US$ m), October 2015 - March 2016 48
Figure 23:Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Upfront and Milestone Payments and Deal Values (US$ m), October 2015 - March 2016 49
Figure 24: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, Number Of Deals, October 2015 - March 2016 51
Figure 25: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, Deal Values (US$ m), October 2015 - March 2016 52
Figure 26:Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, by Upfront and Milestone Payments and Deal Values (US$ m), March 2016 53
Figure 27: Pharmaceuticals & Healthcare, Global, Oncology, Number of Deals and Deal Values (US$ m), October 2015 - March 2016 56
Figure 28: Pharmaceuticals & Healthcare, Global, Central Nervous System, Number of Deals and Deal Values (US$ m), October 2015 - March 2016 60
Figure 29: Pharmaceuticals & Healthcare, Global, Infectious Diseases, Number of Deals and Deal Values (US$ m), October 2015 - March 2016 63
Figure 30: Pharmaceuticals & Healthcare, Global, Cardiovascular, Number of Deals and Deal Values (US$ m), October 2015 - March 2016 66
Figure 31: Pharmaceuticals & Healthcare, Global, Immunology, Number of Deals and Deal Values (US$ m), October 2015 - March 2016 69
Figure 32: Pharmaceuticals & Healthcare, Global, Gastrointestinal, Deals Summary, Number of Deals and Deal Values (US$ m), October 2015 - March 2016 72
Figure 33: Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Deals Summary, Number of Deals and Deal Values (US$ m), October 2015 - March 2016 75
Figure 34: Pharmaceuticals & Healthcare, North America, Number of Deals and Deal Values (US$ m), October 2015 - March 2016 78
Figure 35: Pharmaceuticals & Healthcare, Europe, Number of Deals and Deal Values (US$ m), October 2015 - March 2016 82
Figure 36: Pharmaceuticals & Healthcare, Asia-Pacific, Number of Deals and Deal Values (US$ m), October 2015 - March 2016 85
Figure 37: Pharmaceuticals & Healthcare, Rest of the World, Number of Deals and Deal Values (US$ m), October 2015 - March 2016 88
Figure 38: Pharmaceuticals & Healthcare, Global, Top Financial Advisors, M&A, Number of Deals and Deal Values (US$ m), October 2015 - March 2016 90
Figure 39: Pharmaceuticals & Healthcare, Global, Top Financial Advisors, Equity Offerings, Number of Deals and Deal Values (US$ m), October 2015 - March 2016 92

Report License Types

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.

Report Enquiry

Do you need more information about this report before making a purchase decision or wish to customize this report to suite your requirements?

If yes, then please use the form given below and we will get in touch with you immediately.

Kindly use your official email address and contact number to ensure speedy response.

Name *

Email *

Company

Contact Number *

Report Title *

Your Message

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Drag or click the correct shape to the grey "drop area".